navitoclax

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark
Fierce Biotech
Tue, 04/12/22 - 08:31 pm
AACR
AbbVie
navitoclax
myelofibrosis
blood cancer